Safety and immunogenicity of one or two doses of the rVSVΔG-ZEBOV-GP Ebola virus vaccine in adults and adolescents living with HIV: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial.
Lancet HIVAug 7, 2026 (epub)
Cécile Tremblay, Innocent Valea, Birahim Pierre Ndiaye et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 2, multicentre, double-blind, randomised, placebo-controlled trial evaluated the safety and immunogenicity of the rVSVΔG-ZEBOV-GP Ebola vaccine in 251 adults and adolescents living with HIV. The study found that one dose of the vaccine elicited a 40-fold increase in Ebola-specific antibodies compared to placebo (GMTR 42.90, p<0.0001), while two doses resulted in over a 200-fold increase.
Key findings
- One dose of rVSVΔG-ZEBOV-GP increased GP-ELISA antibodies over 40-fold compared to placebo (GMTR 42.90, p<0.0001).
- In cohort 5, the GP-ELISA geometric mean titre after the second dose was over 200-fold higher than placebo (GMTR 208.66, p<0.0001).
- The GFMI of PRNT titres was 11.51 after one dose and 86.64 after two doses.
- Solicited adverse events were mild to moderate and transient.
Why it matters
Understanding the immunogenicity and safety of the rVSVΔG-ZEBOV-GP vaccine in HIV-infected individuals is crucial, as these populations may be at higher risk during Ebola outbreaks. Effective vaccination strategies can enhance public health responses.